This record was last updated March 4, 2022 (before its estimated June 2024 completion). Its status may not reflect the trial's current state.
Summary
This is a phase III randomized controlled trial comparing the efficacy and safety of FOLFOXIRI versus CapeOX as neoadjuvant regimen in treating patients with middle and upper locally advanced (MRI T3-4 or N+) rectal cancer. This study aims to optimize the neoadjuvant therapy for patients with anus-preserving resectable locally advanced rectal cancer, so as to improve the prognosis of them. It remains unclear about whether FOLFOXIRI or CapeOX neoadjuvant chemotherapy is more effective for locally advanced rectal cancer.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2022-01-07.